Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29079068 | 0.82 | ACACB (0.42) | PSMB5PSMB1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL9609776 | 0.81 | ADRA2A (0.42) | PSMB5GRM2ADRA2AALDH1A1POLB | |
| SCHEMBL18186968 | 0.80 | ACACB (0.39) | GRM2 | |
| SCHEMBL1038378 | 0.79 | GRM2 (0.41) | PSMB5GRM2ADRA2AALDH1A1POLB | |
| SCHEMBL1039192 | 0.77 | ACACB (0.41) | ALDH1A1POLBTSHRNPSR1L3MBTL1 | |
| SCHEMBL3670650 | 0.77 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL2536759 | 0.77 | BACE1 (0.31) | PSMB5PSMB1ALDH1A1 | |
| SCHEMBL29079055 | 0.76 | ACACB (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL3658413 | 0.76 | HTR2C (0.44) | — | |
| SCHEMBL16553415 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041475-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | ADDEX PHARMACEUTICALS S.A. (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | ADDEX PHARMACEUTICALS S.A. (CH) | 2021-07-27 | — | — | US | disclosed |
| CN-105517553-B | Pyrazolo [1,5-a ] pyrimidine-based compounds, compositions comprising the same, and methods of use thereof | 莱西肯医药有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2020-02-06 | — | — | US | disclosed |
| US-9862724-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862724-B2 | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170081330-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-03-23 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-101801951-A | 1 ', 3 ' -disubstituted-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -ones | ORTHO MCNEIL JANSSEN PHARM | 2010-08-11 | — | — | CN | disclosed |
| CN-101801930-A | 1,3-is dibasic-4-phenyl-1 h-pyridin-2-ketone | ORTHO MCNEIL JANSSEN PHARM | 2010-08-11 | — | — | CN | disclosed |
| WO-2009033704-A1 | 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033703-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | GRM2, GRM1, GRIN2C | PSMB5 1352/4885PSMB1 1968/4885GRM2 1/4885 |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | PSMB5 1348/4885PSMB1 1914/4885GRM2 1/4885 |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRIN2C | PSMB5 1316/4885PSMB1 1797/4885GRM2 1/4885 |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | PSMB5 1348/4885PSMB1 1914/4885GRM2 1/4885 |
| US-20170081330-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | PSMB5 3662/4885PSMB1 2917/4885GRM2 967/4885 |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | GRM2, GRM1, GRM3 | PSMB5 1448/4885PSMB1 2032/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.